OPPapers.com Essay Index >> Miscellaneous >> Recent Activities In The Biotechnology Industry Sector
We have many free term papers and essays on Recent Activities In The Biotechnology Industry Sector. We also have a wide variety of research papers and book reports available to you for free. You can browse our collection of term papers or use our search engine.
Recent activities in the Biotechnology Industry Sector. Review of Recent
activities in the Biotechnology Industry Sector : Focusing ...
... In recent years, advances in technology such as in ... The application of advances in
biotechnology in the mining ... Like most business activities, mining has its cons ...
... Recent monthly indicators up to May’07 have ... including bioinformatics, a convergence
of biotechnology and ICT ... innovation and increase R&D activities,' Lee says ...
... effective SCM and manufacturing activities to deliver ... going to be • Generics •
Biotechnology • Outsourcing About ... and the recent acquisitions of European ...
... policies concerning review and inspection activities” (Stat-A ... The recent mergers
have drained Pfizer ... Regulation of the pharmaceutical-biotechnology industry. ...
Submitted by sc0011 on January 21, 2008
Category: Miscellaneous
Words: 1645 | Pages: 7
Views: 199
Popularity Rank: 61,368
Average Member Grade: N/A (Add a Comment / Grade this Paper)
Review of Recent activities in the Biotechnology Industry Sector :
Focusing on Pharmaceuticals and the Company GlaxoSmithKline
Biotechnology can be defined as the industrial application of living organisms or biological techniques developed through basic research . One type of product derived from these techniques is pharmaceuticals. Many pharmaceutical companies exist globally and produce mainly human health related products such as medicines, vaccinations and dental care products.
Due to the nature of the products being produced in the market, the speed at which new technological breakthroughs affect new products and the high levels of competition within the market, the biotechnological pharmaceutical sector is an extremely difficult industry to exist in. The vast sums of investment required in research of new products and the low percentage success rate of these products has lead to the market being dominated by a few key companies. When referring to the pharmaceuticals market the big players are AstraZeneca, GlaxoSmithKline, Pfizer and Novartis. Recent changes to codes of practice and price legislation, could however affect the performance of some of these market leaders.
The body which governs the pharmaceuticals market, ABPI (Association of the British Pharmaceutical Industry) is introducing a new code of practice as of 1st January 2006. One of the key changes is a requirement for all promotional material to prominently include information on the possible adverse reaction of the drug. To include this information on the advertising for medicinal products could harm sales of all of the companies. These side effects could be extremely unlikely to happen; however having negative effects could scare potential customers from using the drug.
The new code is also reducing the number of pages permitted to advertise and promote medicines. Although initially this would save companies money through reduced advertising...
You must Login to view the entire paper.
If you are not a member yet, Sign Up for free!